Antipsychotic: Difference between revisions
>Oskykins No edit summary |
>Oskykins No edit summary |
||
| Line 1: | Line 1: | ||
{{Stub}} | {{Stub}} | ||
'''Antipsychotics''' (also known as '''neuroleptics''' or '''major tranquilizers''')<ref>http://books.google.ca/books?id=Q4hG2gRhy7oC&pg=PA151</ref> are a class of psychiatric medication primarily used to manage [[psychosis]] (including [[Delusions|delusions]], hallucinations, or disordered thought), particularly in [[schizophrenia]] and bipolar disorder | '''Antipsychotics''' (also known as '''neuroleptics''' or '''major tranquilizers''')<ref>http://books.google.ca/books?id=Q4hG2gRhy7oC&pg=PA151</ref> are a class of psychiatric medication primarily used to manage [[psychosis]] (including [[Delusions|delusions]], hallucinations, or disordered thought), particularly in [[schizophrenia]] and bipolar disorder. | ||
First generation antipsychotics, known as typical antipsychotics, were discovered in the 1950s. Most second generation drugs, known as atypical antipsychotics, have been developed more recently, although the first atypical antipsychotic, [[clozapine]], was discovered in the 1950s and introduced clinically in the 1970s. Both generations of medication tend to block receptors in the brain's [[dopamine]] pathways but atypicals tend to act on [[serotonin]] receptors as well. | First generation antipsychotics, known as typical antipsychotics, were discovered in the 1950s. Most second generation drugs, known as atypical antipsychotics, have been developed more recently, although the first atypical antipsychotic, [[clozapine]], was discovered in the 1950s and introduced clinically in the 1970s. Both generations of medication tend to block receptors in the brain's [[dopamine]] pathways but atypicals tend to act on [[serotonin]] receptors as well. | ||
| Line 6: | Line 6: | ||
Notable and relatively common adverse effects of antipsychotics include extrapyramidal symptoms (which involve motor control), hyperprolactinaemia (primarily in typicals), weight gain and metabolic abnormalities (mostly in atypicals).<ref name = "SCZ">{{cite web | url = http://emedicine.medscape.com/article/288259-overview | title = Schizophrenia | author = Frankenburg FR, Dunayevich E, Albucher RC, Talavera F | publisher = emedicine.medscape.com | accessdate = 2013-10-02 }}</ref> | Notable and relatively common adverse effects of antipsychotics include extrapyramidal symptoms (which involve motor control), hyperprolactinaemia (primarily in typicals), weight gain and metabolic abnormalities (mostly in atypicals).<ref name = "SCZ">{{cite web | url = http://emedicine.medscape.com/article/288259-overview | title = Schizophrenia | author = Frankenburg FR, Dunayevich E, Albucher RC, Talavera F | publisher = emedicine.medscape.com | accessdate = 2013-10-02 }}</ref> | ||
==See also== | |||
*[[Psychedelics]] | *[[Psychedelics]] | ||
*[[Quetiapine]] | *[[Quetiapine]] | ||
Revision as of 10:52, 2 September 2015
 |
This article is a stub. As such, it may contain incomplete or wrong information. You can help by expanding it. |
Antipsychotics (also known as neuroleptics or major tranquilizers)[1] are a class of psychiatric medication primarily used to manage psychosis (including delusions, hallucinations, or disordered thought), particularly in schizophrenia and bipolar disorder.
First generation antipsychotics, known as typical antipsychotics, were discovered in the 1950s. Most second generation drugs, known as atypical antipsychotics, have been developed more recently, although the first atypical antipsychotic, clozapine, was discovered in the 1950s and introduced clinically in the 1970s. Both generations of medication tend to block receptors in the brain's dopamine pathways but atypicals tend to act on serotonin receptors as well.
Notable and relatively common adverse effects of antipsychotics include extrapyramidal symptoms (which involve motor control), hyperprolactinaemia (primarily in typicals), weight gain and metabolic abnormalities (mostly in atypicals).[2]
See also
References
- ↑ http://books.google.ca/books?id=Q4hG2gRhy7oC&pg=PA151
- ↑ Frankenburg FR, Dunayevich E, Albucher RC, Talavera F. "Schizophrenia". emedicine.medscape.com. Retrieved 2013-10-02.